Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Xeraya Capital

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 25
Average round size
info
The average size of a deal this fund participated in
$42M
Portfolio companies 17
Rounds per year 2.50
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.32
Exits 5
Key employees 1

Areas of investment

  • Biotechnology
  • Health Care
  • Manufacturing
  • Medical Device
  • Therapeutics
Summary

The company was established in Asia in Malaysia. The main department of described VC is located in the Kuala Lumpur.

Considering the real fund results, this VC is 26 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2016. Despite it in 2019 the fund had an activity. Deals in the range of 10 - 50 millions dollars are the general things for fund. This Xeraya Capital works on 2 percentage points more the average amount of lead investments comparing to the other organizations. The fund is generally included in less than 2 deals every year. The top amount of exits for fund were in 2018.

For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight ViewRay, Acutus Medical, Rapid Micro Biosystems. Among the most popular fund investment industries, there are Health Diagnostics, Therapeutics. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups.

The overall number of key employees were 1.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Xeraya Capital, startups are often financed by OrbiMed, Khosla Ventures, Connecticut Innovations. The meaningful sponsors for the fund in investment in the same round are OrbiMed, OUP (Osage University Partners), Kearny Venture Partners. In the next rounds fund is usually obtained by OrbiMed, Kearny Venture Partners, Deerfield Capital Management.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Xeraya Capital:
Typical Co-investors
Xeraya Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Xeraya Capital:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Berggruen Holdings New York, New York, United States
Cascade Investment Fund -
Donghan International -
Good Capital New York, Tarrytown, United States
Haida Lianchuang Wuhan Touzi China, Hubei, Wuhan
Linden Asset Management Pennsylvania, Philadelphia, United States
Omaha Capital Nebraska, Omaha, United States
Plum Alley New York, New York, United States
Road Ventures Geneva, Geneve, Switzerland

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Greenlight Biosciences

Agriculture
AgTech
Biotechnology
Chemical
Fuel
Sustainability
$125M03 Feb 2022 Massachusetts, United States

OncoMyx Therapeutics

Biotechnology
Health Diagnostics
Medical
Therapeutics
$50M09 Dec 2021 Phoenix, Arizona, United States

OncoMyx Therapeutics

Biotechnology
Health Care
Therapeutics
$50M08 Dec 2021 Tempe, Arizona, United States

Imago BioSciences

Biotechnology
Life Science
Medical
$80M19 Nov 2020 California, United States

InterVenn

Biotechnology
Life Science
$34M16 Nov 2020 South San Francisco, California, United States

Congenica

Bioinformatics
Biotechnology
Genetics
Health Care
Medical
$50M09 Nov 2020 Cambridge, England, United Kingdom

Rapid Micro Biosystems

Biotechnology
Manufacturing
Pharmaceutical
$120M20 May 2020 Massachusetts, United States

Greenlight Biosciences

Agriculture
AgTech
Biotechnology
Chemical
Fuel
Sustainability
$17M12 May 2020 Massachusetts, United States

Aria CV

Health Care
Medical Device
Wellness
$31M25 Feb 2020 Saint Paul, Minnesota, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Xeraya Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: